The story of Sildenafil presents a nuanced case for investors in the medicinal sector. While initially a blockbuster success, creating huge profits, the patent end and the subsequent arrival of cheaper alternatives have significantly changed revenue. This presents questions about the long-term sustainability of analogous therapeutic developments an